Skip to main content

Table 4 Percentage positive antibody responses of the four representative DENV peptides of broadly immunogenic E protein epitopes to human sera of four DENV serotypes

From: Natural immunogenic properties of bioinformatically predicted linear B-cell epitopes of dengue envelope and pre-membrane proteins

Serotype of the sera

P4/E (72–88)

P5/E (89–104)

P14/E (394–410)

P15/E (418–434)

P17/E (458–474)

 

DENV1

SRCPTQGEATLVEEQDA

DENV1

NFVCRRTFVDRGWGNG

DENV1

KGSSIGKMFEATARGAR

DENV1

TWADFGSIGGVFTSVGK

DENV1

IGILLTWLGLNSRSTSL

DENV1

12 (100%)

12 (100%)

10 (83%)

12 (100%)

10 (83%)

DENV2

12 (100%)

12 (100%)

10 (83%)

12 (100%)

9 (75%)

DENV3

12 (100%)

12 (100%)

12 (100%)

12 (100%)

9 (75%)

DENV4

12 (100%)

12 (100%)

12 (100%)

12 (100%)

9 (75%)

 

DENV2

RCPTQGEPSLNEEQDKRF

DENV2

KRFVCKHSMVDRGWGNGCGL

DENV2

KKGSSIGQMIETTMRGAK

DENV2

AILGDTAWDFGSLGGVF

DENV2

IITWIGMNSRSTSLSVSL

DENV1

12 (100%)

12 (100%)

10 (83%)

0 (0%)

12 (100%)

DENV2

12 (100%)

12 (100%)

10 (83%)

0 (0%)

12 (100%)

DENV3

12 (100%)

12 (100%)

10 (83%)

0 (0%)

12 (100%)

DENV4

12 (100%)

12 (100%)

10 (83%)

0 (0%)

12 (100%)

 

DENV3

SRCPTQGEAILPEEQDQNH

DENV3

CKHTYVDRGWGNGCGLF

DENV3

KKGSSIGKMFEATARGAR

DENV3

WDFGSVGGVLNSLGKMVH

DENV3

IGIGVLLTWIGLNSK

DENV1

12 (100%)

0 (0%)

12 (100%)

6 (50%)

0 (0%)

DENV2

12 (100%)

0 (0%)

12 (100%)

9 (75%)

0 (0%)

DENV3

12 (100%)

0 (0%)

12 (100%)

10 (83%)

0 (0%)

DENV4

12 (100%)

0 (0%)

12 (100%)

6 (50%)

3(25%)

 

DENV4

TRCPTQGEPYLKEEQDQQY

DENV4

CRRDVVDRGWGNGCGLF

DENV4

SIGKMFESTYRGAKRMAI

DENV4

WDFGSVGGLFTSLGKAVH

DENV4

LVLWIGTNSRNTSMAM

DENV1

2 (17%)

9 (75%)

0 (0%)

10 (83%)

0 (0%)

DENV2

10 (83%)

9 (75%)

0 (0%)

12 (100%)

0 (0%)

DENV3

2 (17%)

10 (83%)

0 (0%)

9 (75%)

1 (8%)

DENV4

12 (100%)

6 (50%)

0 (0%)

9 (75%)

0 (0%)

Serotype of the sera

P2/E (30–46)

P3/E (60–76)

P13/E (377–393)

P16/E (424–440)

 

DENV1

CVTTMAKDKPTLDIELL

DENV1

CIEAKISNTTTDSRCPT

DENV1

YIVVGAGEKALKQCWFK

DENV1

SIGGVFTSVGKLVHQVF

DENV1

12 (100%)

10 (83%)

0 (0%)

0 (0%)

DENV2

9 (75%)

0 (0%)

12 (100%)

12 (100%)

DENV3

6 (50%)

9 (100%)

9 (75%)

10 (83%)

DENV4

0 (0%)

12 (100%)

9 (75%)

10 (83%)

 

DENV2

SCVTTMAKNKPTLDFELI

DENV2

EIKITPQSSITEAFLTGY

DENV2

FGDSYIIIGVEPGQLKL

DENV2

WDFGSLGGVFTSIGKALH

DENV1

3 (25%)

10 (83%)

1 (8%)

0(0%)

DENV2

12 (100%)

12 (100%)

6 (50%)

0 (0%)

DENV3

6 (50%)

12 (100%)

0 (0%)

0 (0%)

DENV4

0 (0%)

9 (75%)

6 (50%)

0 (0%)

 

DENV3

GCVTTMAKNKPTLDIEL

DENV3

LCIEGKITNVTTDSR7

DENV3

KALKINWYKKGSSIGKMF

DENV3

VLNSLGKMVHQIFGSAY

DENV1

0 (0%)

0 (0%)

1 (8%)

0 (0%)

DENV2

0 (0%)

0 (0%)

5 (42%)

2 (17%)

DENV3

4 (33%)

0 (0%)

12 (100%)

0 (0%)

DENV4

5 (42%)

0 (0%)

0 (0%)

3 (25%)

 

DENV4

GCVTTMAQGKPTLDFEL

DENV4

SISNITTATRCPTQQGEPY

DENV4

FDSYIVIGVGNSALTLH

DENV4

WDFGSVGGLFTSLGKAVH

DENV1

2 (17%)

9 (75%)

0 (0%)

0 (0%)

DENV2

10 (83%)

3 (25%)

1 (8%)

0 (0%)

DENV3

3 (25%)

10 (83%)

0 (0%)

0 (0%)

DENV4

6 (50%)

12 (100%)

0 (0%)

0 (0%)

  1. Number of sera samples giving positive responses out of twelve sera samples tested per serotype (DENV1, DENV2, DENV3, DENV4), and its percentage (%) are shown. The peptide sequences from each serotype for a respective epitope are shown. The corresponding epitope/peptide sequences from cross serotypes are based on the peptide arrays; DENV1 (Singapore/S275/1990 (NR-4551)), DENV2 (New Guinea C (NR-507)), DENV3 (Sleman/1978 (NR-511)), DENV4 (Dominica/814669/1981 (NR-512))